All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99

ViewsDownloads

Relative Articles

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study

Outcomes of Optimized over Standard Protocol of Rabbit Antithymocyte Globulin for Severe Aplastic Anemia: A Single-Center Experience

Colonic EBV-Associated Lymphoproliferative Disorder in a Patient Treated with Rabbit Antithymocyte Globulin for Aplastic Anemia

Colonic EBV-Associated Lymphoproliferative Disorder in a Patient Treated with Rabbit Antithymocyte Globulin for Aplastic Anemia

Long-term outcome of 25 children and adolescents with severe aplastic anemia treated with antithymocyte globulin

Long-term outcome of 25 children and adolescents with severe aplastic anemia treated with antithymocyte globulin

Allogeneic and autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non-Hodgkin lymphoma

Successful Hematopoietic Stem Cell Transplantation Following a Cyclophosphamide-Containing Preparative Regimen with Concomitant Phenobarbital Administration

Allogeneic bone marrow transplantation for severe aplastic anemia patients with risk factors for poor prognosis: is fludarabine a requirement?

Acquired hemoglobin H disease in a patient with aplastic anemia evolving into acute myeloid leukemia

More...

A retrospective comparison of cyclophosphamide plus antithymocyte globulin with cyclophosphamide plus busulfan as the conditioning regimen for severe aplastic anemia

DOI: 10.1590/S0100-879X2009000300005

Keywords: aplastic anemia, allogeneic stem cell transplantation, conditioning regimen, atg-cy, bu-cy.

Full-Text   Cite this paper   Add to My Lib

Abstract:

allogeneic hematopoietic stem cell transplantation (ahsct) is the treatment of choice for young patients with severe aplastic anemia (saa). the association of antithymocyte globulin (atg) and cyclophosphamide (cy) is the most frequently used conditioning regimen for this disease. we performed this retrospective study in order to compare the outcomes of hla-matched sibling donor ahsct in 41 patients with saa receiving cyclophosphamide plus atg (atg-cy, n = 17) or cyclophosphamide plus busulfan (bu-cy, n = 24). the substitution of bu for atg was motivated by the high cost of atg. there were no differences in the clinical features between the two groups, including age, gender, cytomegalovirus status, abo match, interval between diagnosis and transplant, and number of total nucleated cells infused. no differences were observed in the time to neutrophil and platelet engraftment, or in the risk of veno-occlusive disease and hemorrhage. however, there was a higher risk of mucositis in the bu-cy group (71 vs 24%, p = 0.004). there were no differences in the incidence of neutrophil and platelet engraftment, acute and chronic graft-versus-host disease, and transplant-related mortality. there was a higher incidence of late rejection in the atg-cy group (41 vs 4%, p = 0.009). although the atg-cy group had a longer follow-up (101 months) than the bu-cy group (67 months, p = 0.04), overall survival was similar between the groups (69 vs 58%, respectively, p = 0.32). we conclude that the association bu-cy is a feasible option to the conventional atg-cy regimen in this population.

Full-Text

comments powered by Disqus